HIPEC in gastric carcinomatosis: the scientific evidence
HIPEC for peritoneal carcinomatosis of gastric origin is controversial. Some studies, such as CYTO-CHIP, have found a benefit in very selected patients.
Results of recent studies
CYTO-CHIP study (France): Surgery+HIPEC vs chemotherapy alone in limited gastric carcinomatosis. Median survival: 18.8 vs 14.3 months (p=0.046)
Asian meta-analyses: Selected patients (low PCI, complete cytoreduction): median survival >24 months vs 12 months without HIPEC
Strict selection criteria
• PCI <7: Limited carcinomatosis
• Possibility of complete cytoreduction (CC-0)
• No extra-abdominal metastases
• Good functional status (ECOG 0-1)
• Response to neoadjuvant chemotherapy
Experience at Quenet Torrent Institute
We have treated selected cases of gastric carcinomatosis with cytoreductive surgery+HIPEC, with survival above the published average. What weighs most in these results is selecting patients well.
Carcinomatosis from gastric cancer? A team with experience in this surgery can assess whether you are a candidate. See stomach cancer. Request a second opinion.